Community Bank N.A. Acquires 940 Shares of Eli Lilly and Company $LLY

Community Bank N.A. boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 28.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,294 shares of the company’s stock after buying an additional 940 shares during the period. Community Bank N.A.’s holdings in Eli Lilly and Company were worth $3,276,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in LLY. Clark Capital Management Group Inc. boosted its stake in Eli Lilly and Company by 0.3% during the 3rd quarter. Clark Capital Management Group Inc. now owns 139,007 shares of the company’s stock valued at $106,063,000 after purchasing an additional 366 shares during the last quarter. Clear Street Group Inc. purchased a new stake in shares of Eli Lilly and Company in the third quarter worth approximately $30,482,000. Ausdal Financial Partners Inc. lifted its holdings in shares of Eli Lilly and Company by 42.1% in the third quarter. Ausdal Financial Partners Inc. now owns 6,352 shares of the company’s stock valued at $4,846,000 after purchasing an additional 1,881 shares in the last quarter. Banco Bilbao Vizcaya Argentaria S.A. lifted its holdings in shares of Eli Lilly and Company by 74.4% in the third quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 72,043 shares of the company’s stock valued at $54,656,000 after purchasing an additional 30,730 shares in the last quarter. Finally, Chilton Investment Co. Inc. boosted its position in shares of Eli Lilly and Company by 295.6% during the third quarter. Chilton Investment Co. Inc. now owns 12,489 shares of the company’s stock valued at $9,529,000 after buying an additional 9,332 shares during the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Stock Up 0.8%

Shares of NYSE:LLY opened at $985.10 on Friday. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,133.95. The company has a market capitalization of $930.74 billion, a PE ratio of 42.92, a price-to-earnings-growth ratio of 1.15 and a beta of 0.40. The business has a fifty day moving average price of $1,037.28 and a two-hundred day moving average price of $950.80. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. The company had revenue of $19.29 billion for the quarter, compared to analysts’ expectations of $17.85 billion. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The business’s revenue for the quarter was up 42.6% compared to the same quarter last year. During the same period in the previous year, the business posted $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on LLY shares. UBS Group reiterated a “buy” rating on shares of Eli Lilly and Company in a report on Monday, February 2nd. Guggenheim lifted their price objective on shares of Eli Lilly and Company from $1,161.00 to $1,168.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Jefferies Financial Group set a $1,300.00 target price on shares of Eli Lilly and Company and gave the stock a “buy” rating in a research note on Friday. Loop Capital set a $1,200.00 target price on shares of Eli Lilly and Company in a report on Tuesday, February 10th. Finally, Bank of America dropped their price target on shares of Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating on the stock in a research report on Monday, December 15th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $1,229.59.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Big, long‑term capacity bet in China: Lilly’s planned $3 billion, decade‑long buildout in China is being viewed as a strategic way to secure supply, win share in the fast‑growing GLP‑1 market there, and defend margins versus local competitors — a clear revenue runway catalyst. The Real Reason Eli Lilly Is Pouring $3 Billion Into China
• Positive Sentiment: Policy and access tailwinds: CMS expansion of Medicare access to Zepbound and Mounjaro broadens the addressable patient base and reduces a key barrier to volume growth for Lilly’s injectable GLP‑1s. This supports upside to near‑term sales forecasts. Eli Lilly (LLY) and CMS Expand Medicare Access to Zepbound and Mounjaro
• Positive Sentiment: Commercial & product expansion moves: Employer Connect and LillyDirect aim to unlock employer coverage and lower out‑of‑pocket friction for Zepbound, which could materially increase uptake if employers adopt the program. Combined with positive head‑to‑head oral GLP‑1 data for orforglipron, this strengthens the multi‑product growth story. Eli Lilly’s Employer Push Could Unlock New GLP-1 Demand
• Positive Sentiment: Clinical pipeline progress: Lilly advanced a Phase‑1 study of eloralintide in high‑risk kidney patients — additional indications or safety/efficacy data can expand uses and support valuation beyond obesity/diabetes franchises. Lilly Advances Eloralintide Study in High-Risk Kidney Patients: What Investors Should Know
• Positive Sentiment: Manufacturing footprint expansion: Smaller regional investments (e.g., Korea, Japan plant expansion) further de‑risk supply and support global launch scale for next‑gen GLP‑1s. These moves reduce disruption risk and help defend market share. Eli Lilly invests $500 million in Korea’s biotech growth
• Neutral Sentiment: Valuation / stock structure chatter: Continued outperformance has people speculating about a stock split (accessibility for retail investors), which is psychology‑driven and may influence retail flows but doesn’t change fundamentals. 3 Stocks That Could Be Next to Announce a Stock Split
• Negative Sentiment: Safety/supply headline risk: Lilly warned about an unknown impurity found in compounded tirzepatide mixed with vitamin B12 — this raises short‑term PR/regulatory risk and could spur use‑restrictions or additional scrutiny of compounding practices. Using Obesity Drug? Eli Lilly Flags Unknown Impurity Found In Compounded Weight Loss Drugs With Vitamin B12
• Negative Sentiment: Momentum concerns: Some analysts/commentary note weakening trading momentum since November — a reminder that lofty multiples and rate/flow dynamics can pressure the stock if sentiment turns. Eli Lilly Reaching For Peak GLP-1 Euphoria: Rotten Trading Momentum Since November

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.